A prognostic model using the neutrophil-albumin ratio and PG-SGA to predict overall survival in advanced palliative lung cancer

Table 1 Demographics and clinical characteristics of patients with palliatively treated lung cancer

Demographic or Characteristic	Main Training Cohort (n = 223)		Validation Cohort (n = 72)
Demographic or Characteristic	No. of Patients	%	No. of Patients	%
Sex
Male	164	73.5	56	77.7
Female	59	26.5	16	22.3
Age, y
< 60	89	39.9	28	38.9
≥ 60	134	60.1	44	61.1
KPS, %
< 70	63	28.3	19	26.4
≥ 70	160	71.7	53	73.6
Tumour histology
Squamous carcinoma	67	30.1	16	22.2
Adenocarcinoma	122	54.7	44	61.1
Small cell lung cancer	34	15.2	12	16.7
Clinical stage
Stage III	28	12.6	11	15.3
Stage IV	195	87.4	61	84.1
Therapy method
Palliative chemoradiotherapy	92	41.3	33	45.9
Targeted or immunotherapy	56	25.1	20	27.7
Supportive care	75	33.6	19	26.4
Loss of appetite
No	126	56.5	42	58.3
Yes	97	43.5	30	41.7
Cancer pain
No	195	87.4	58	80.6
Yes	28	12.6	14	19.4
Diarrhoea
No	211	94.6	69	95.8
Yes	12	5.4	3	4.2
Nausea
No	183	82.1	61	84.7
Yes	40	17.9	11	15.3
Vomiting
No	190	85.2	58	80.6
Yes	33	14.8	14	19.4
NLR
Median	4.5		4.2
IQR	2.7–7.7		2.3–8.4
NAR
Median	0.13		0.13
IQR	0.08–0.22		0.08–0.21
PG-SGA score
Median	12		13
IQR	8–15		8–16

Abbreviations: KPS Karnofsky Performance Status, NLR Neutrophil-to-lymphocyte Ratio, NAR Neutrophil-albumin Ratio, PG-SGA Patient-Generated Subjective Global Assessment, IQR Interquartile Range

ISSN: 1472-684X